Recent efforts to identify alternative targets in FLT3-ITD AML lead to the identification of candidates such as PU.1 [21], NFATc1 [22], SIRT1 [23], PIM [24], FES [25], SYK [26], and BTK [27]. This evidence concerns the gene SIRT1 and acute myeloid leukemia.